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CD8/ T cells may play a beneficial role in human immunodeficiency virus (HIV)-infected patients by two mechanisms:
HIV-specific cytotoxic activity and secretion of a soluble mediator(s) that inhibits HIV replication in vitro. Here we character-
ized both activities mediated by an HIV p24gag-specific cytotoxic T lymphocyte (CTL) CD8/ clone derived from an HIV-
infected patient. When the CTL clone was mixed with HIV-infected autologous CD4/ T cells, viral replication was suppressed.
This viral inhibition was observed in heterologous CD4/ T cells and when CD8/ and CD4/ populations were separated
by a semipermeable membrane, demonstrating the involvement of a diffusible factor(s). The lysis of autologous HIV-infected
T cells was also detected. However, HIV suppression was more efficient when CD4/ and CD8/ T cells shared major
histocompatibility complex alleles and were in direct contact. Thus, one and the same CD8/ T cell population can mediate
both lysis of HIV-infected targets and nonlytic suppression of HIV replication. These results underline the multiple roles of
CD8/ T lymphocytes in the suppression of HIV-infected cells. q 1996 Academic Press, Inc.
Virus-specific, major histocompatibility complex (MHC) cently, IL-16 and a combination of RANTES, macrophage
class I-restricted CD8/ cytotoxic T lymphocytes (CTL) inflammatory protein 1a (MIP-1a), and MIP-1b were
have been shown to play a role in recovery from viral shown to inhibit HIV replication (15, 16). Most studies
infections (1). Recognition of appropriate target cells by argued that the HIV-inhibitory activity was distinct from
CD8/ T cells leads to both direct lysis of infected cells direct cytolysis (for review, 17, 18). Although one study
and secretion of soluble factors with antiviral function, demonstrated that the CD8/ T cells which control virus
such as interferon-g or tumor necrosis factor-a (2–4). replication had the same phenotype as CTL, polyclonal
A vigorous CTL response has been detected in people populations were used in these experiments, which com-
infected with the human immunodeficiency virus (HIV). plicated the analysis (19). Based on the known cytokines
The effector cells express the CD8 cell surface marker, secretion by virus-specific CTL (3, 4, 20–23), we postu-
are MHC class I restricted, and are directed to most lated that the same CD8/ T cell should be able to both
structural and regulatory viral proteins (for review, 5, 6). lyse infected targets and secrete HIV-inhibitory factor(s).
Virus-specific CTL have been temporally associated with To test our hypothesis, we derived an HIV-specific CD8/
reduction of virus load during primary HIV infection in T cell clone. We founded that this clonal CD8/ T cell
humans, as well as in simian immunodeficiency virus- population exhibited both cytotoxic activity and ability to
infected rhesus macaques (7–9). An increased rate of inhibit HIV replication in acutely infected CD4/ T cells,
progression to AIDS was observed in asymptomatic HIV- therefore direct lysis and secretion of HIV-inhibitory fac-
infected adults who had no primary HIV p55gag-specific tors can be mediated by the same CD8/ T cell.
CTL activity (10). CTL line 141 was derived from an HIV-infected patient
Another activity of CD8/ T lymphocytes is the inhibi- (24). PBMC were seeded at 50 cells per well in 96-well
tion of HIV replication in vitro described by Walker et al. plates and cultured with phytohemagglutinin (PHA-p, 2
(11). A soluble inhibitor released by these cells has been mg/ml; Difco, Coger, France) and 106/ml irradiated (50
implicated in mediating this antiviral effect (12–14). Re- Gy) allogeneic uninfected PBMC as feeder cells. Plates
were fed once a week with fresh medium. Subsequent
stimulations were antigen specific and performed every
1 To whom correspondence and reprint requests should be ad- 3 to 4 weeks as follows: autologous B-EBV cells weredressed at the Unite´ de Virologie et Immunologie Cellulaire, Institut
incubated overnight with antigenic peptide 25-17 (KTL-Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France. Fax:
(33)1 40 61 30 12; E-mail: riviere@pasteur.fr. RAEQASQEVKNWMTET, aa 302–320 from HIV p24gag,
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Ref. 25) or 5045 (QASQEVKNW aa 308–316 from HIV
p24gag) at 1 mg/ml, then washed and irradiated (100 Gy).
The stimulator to effector ratio was 1/1, and allogeneic
irradiated feeder cells were added at a concentration
of 106 cells/ml. One to three weeks after the second
stimulation, the growing wells were screened for CTL
activity against peptide-coated autologous B-EBV cell
line, using uncoated B-EBV as control. Flow cytometry
analysis demonstrated that the 141 cell line was 99.8%
CD3/ CD40 CD8/ TCRab/ TCRgd0 (Fig. 1 and data not
shown). Within peptide 25-17, the 9-mer sequence QAS-
QEVKNW (peptide 5045, aa 308–316) was the shortest
sequence recognized, and the lowest peptide concentra-
tion required for maximal target cell sensitization was 1
ng/ml for the 9-mer. Presentation of antigenic peptide to
CTL line 141 is restricted by an MHC class I molecule,
HLA-C, not yet defined or detected by genetic or sero-
logic techniques (Buseyne et al., submitted).
Using a panel of antibodies specific for TCR-Vb chains
the uniform expression of TCR Vb13 was stable over
several months (Figs. 1A and 1B). To further characterize
the clonality of the 141 Vb13 T cells, both CDR3 size
distribution of the Vb13 transcripts and the Jb segments
associated with Vb13 were analyzed in a run-off method
previously described (30). By contrast to the classical
Gaussian-like profile obtained from a control donor’s
PBMC, the Vb13-Cb CDR3 size profile obtained from 141
T cells consisted in a single peak with a CDR3 size
corresponding to 9 amino acids (Fig. 1C). When the 13
Jb primers were used to refine the molecular analysis of
141 Vb13-Cb transcripts, only Jb1.2 yielded a signal, also
composed of a peak corresponding to the expected size
of 9 amino acids, whereas Gaussian-like patterns were
obtained from control PBMC with all Jb primers (Fig. 1D).
Altogether, these results provide evidence of clonality for
141 CTL cells. FIG. 1. Phenotypical and molecular characterization of the TCR from
clone 141. (A) The expression of Vb13 TCR element among 141 cellsTo determine the capacity of the HIV-specific CTL
was determined by FACS analysis, using the FITC-conjugated diversiTclone 141 to suppress viral replication, CD4/ T cell lines
bV13 mAb (T cell diagnostic; Bioadvance, Emerainville, France). Sampleswere infected with HIV-1 and mixed with CD8/ T cell were analyzed on a FACScan cytometer using Lysis II software (Becton
clone 141 restimulated 7 days before. HIV production Dickinson). The histogram profile of Vb13 fluorescence and that of an
was monitored by the presence of RT activity in the su- irrelevant control mAb are shown in black and white, respectively. (B)
The coexpression of TCR Vb13 region and CD8 molecule by two-colorpernatant (31). CD4/ T cell lines were derived from HIV-
immunofluorescence using FITC-conjugated anti-TCR Vb13 and PE-con-1-infected patient EM47 and from an HIV-seronegative
jugated Leu2a (anti-CD8; Becton Dickinson, Le Pont de Claix, France)adult (S26). EM47 CD4/ T cells expressed HLA-A30, specific mAbs is represented on the dot plot analysis. (C and D) Distribu-
A68, B53, and Cw4; S26 CD4/ T cells expressed HLA- tion, measured as relative fluorescence intensity, of the aa size of the
A29, A32, B7, B17, and Cw7. When clone 141 was added CDR3 for the run-off reaction products using Cb (C) or the Jb1.2 (D)
fluorescent primers. Each peak corresponds to a defined CDR3 size.to autologous HIV-infected CD4/ T targets, no viral pro-
Patterns on the bottom left correspond to the profile of 141 and patternsduction could be detected at CD8 to CD4 ratios of 10/1
in the insets correspond to fresh donor’s profiles. Total RNA from CTLor 3/1, and at a ratio of 1/1 viral production was delayed clone 141 was prepared as previously described (26) and reverse tran-
(Fig. 2A). CTL were also able to reduce viral replication scribed using the Boerhinger Mannheim cDNA synthesis kit. cDNA was
in HLA-class I mismatched CD4/ T cells, but with a amplified by PCR using Vb13 5* primer and Cb 3* primers (27). PCR
products were subjected to a run-off reaction using a fluorescent Cbreduced efficiency (Fig. 2B). As an example, inhibition of
(5* GGTGTGGGAGAATTCTGCTTCTGA 3* ) or Jb1.2 3* primer (28) asviral replication at a CD8 to CD4 ratio of 3 was complete
previously described (29). Separation and analysis of the size of the run-in autologous CD4/ T cells, but partial in heterologous off products, depending on the CDR3 size, were performed using Applied
cells (Fig. 2). This difference in HIV inhibitory activity Biosystem 373A DNA sequencer and specially designed software (Im-
against autologous and heterologous CD4/ T cell lines munoscope; C. Pannetier, Paris, France).
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FIG. 2. CD8/ CTL clone 141 inhibits HIV replication in autologous and heterologous CD4/ T cell lines. In order to derive CD4/ T cell lines,
PBMC were depleted of CD8/ T cells using magnetic beads coated with anti-CD8 mAb (Immunotech, Marseille, France) following the manufacturer’s
instructions, then seeded at 5 1 105 cells in 24-well plates and stimulated with PHA-p (2 mg/ml) and allogeneic irradiated feeder cells (106/ml).
They were restimulated every 3 or 4 weeks with PHA-p. Cell lines were 99% CD4/CD3/ as shown by flow cytometry. CD8/ T cell clone and the
CD4/ T cell lines were cultured in RPMI 1640 supplemented with 5% human AB serum (ETS, Les Ulis, France), 2 mM L-glutamine, nonessential
amino acids (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL), and 100 IU/ml rIL2 (RU49637, a generous gift from Dr. D. Lando, Roussel Uclaf,
Romainville, France). A stock of HIV-1Lai grown in PHA-p-activated PBMC from an HIV-seronegative donor was used to infect the CD4/ T cell lines.
CD4/ T cell lines were incubated with HIV (3 to 10 1 104 cpm of RT activity for 106 cells) and polybrene (5 mg/ml), in a small volume for 2 hr at
377 and washed. Infected cells (105) were seeded in 24-well plates and CD8/ T cell clone was added at various concentrations in a final volume
of 1 ml. Uninfected CD4/ or CD8/ T lymphocytes were used as negative control, and HIV-infected CD4/ T cell lines alone were used as positive
control. Culture supernatants were changed two or three times a week and stored at 0207 until RT activity was assayed using the technique
described by Schwartz et al. (31). RT activity is expressed in cpm per 50 ml. Results from one representative experiment are shown. Background
RT activity in wells containing CD8/ or uninfected CD4/ alone was 1100 cpm. (A) Clone 141 cocultured with HIVLAI-infected autologous EM47
CD4/ T cell line. (B) Clone 141 cocultured with HIVLAI-infected heterologous S26 CD4/ T cell line.
was observed in five independent experiments where The mode of action of HIV-inhibitory CD8/ cells is still
a matter of debate. Both MHC-restricted and non-MHC-both CD4/ T cells were tested in parallel. But both CD4/
T cell lines were equally sensitive to HIV inhibition by restricted mechanisms have been reported; in most re-
ports suppressive activity was higher in MHC-restrictedother CD8/ T populations, derived from unrelated unin-
fected subjects (data not shown). So the higher reverse conditions (11, 13, 19, 20, 35–37). Some investigators
reported no contribution of soluble factors (35) or thesetranscriptase (RT) activity produced by CD4/ T cell line
S26 had probably no major influence on HIV inhibition mediators alone were active but less than CD8/ T cells
themselves (12, 13, 37, 38). Here we report that a mono-by CD8/ T cell clone 141.
The control of HIV replication was also observed when clonal CD8/ T cell population reproducibly exhibited
higher inhibitory activity against autologous CD4/ Tclone 141 was separated from autologous or heterolo-
gous CD4/ T cell lines by a 0.4-mm pore size filter in cells than against heterologous CD4/ T cells or CD4/
T cells separated by a semipermeable membrane (Figs.transwell cultures (Fig. 3). In both situations where clone
141 and HIV-infected CD4/ T cell line were HLA 2 and 3), and this phenomenon was reproducible (data
not shown). As these HIV inhibition assays were con-matched (Fig. 3A) or mismatched (Fig. 3B), viral produc-
tion was observed at CD8 to CD4 ratios of 3 to 1 and 1 ducted in parallel, neither interindividual variations (39)
nor laboratory differences in protocols could be invokedto 1. The inhibition of viral replication was only observed
at a CD8 to CD4 ratio of 10 to 1. Thus, clone 141 was to explain these differences. In conclusion, cell contact
and MHC compatibility with HIV-infected CD4/ increaseable to control HIV replication in a MHC-independent
manner and secretion of soluble inhibitor(s) was involved the suppressive activity of T cell clone 141.
It could be argued that the control of viral replicationin this activity. A recent report suggested that the chemo-
kines Rantes, MIP-1a, and MIP-1b are responsible for in autologous CD4/ T cell line occurred because in-
fected cells were lysed by CTL clone 141. As shown inthe antiviral activity of CD8/ T cells (16). We have been
able to detect the secretion of RANTES and MIP-1b by Fig. 4, clone 141 lysed autologous CD4/ T cell line
coated with the cognate peptide (Fig. 4A) or autologousELISA in the supernatants of clone 141 (between 1 and
2 ng/ml at cell concentration of 106/ml). However, it is HIV-infected CD4/ T cells (Fig. 4B), but was unable to
lyse the HLA-class I mismatched CD4/ T cell line thatvery unlikely that these chemokines are the suppressive
factors in this system because the T-cell-adapted HIVLai has been used in HIV inhibition assay, coated with the
cognate peptide or infected with HIV (Fig. 4). Thus instrain tested here uses fusin as the coreceptor and is
therefore insensitive to RANTES, MIP-1a, and MIP-1b our experimental system, allogeneic or nonspecific lytic
mechanisms do not account for the suppression of HIVinhibition (16, 32–34).
AID VY 8223 / 6a21$$$442 10-04-96 03:37:47 vira AP: Virology
251SHORT COMMUNICATION
FIG. 3. CD8/ CTL clone 141 inhibits HIV replication: involvement of diffusible factors. CD4/ T cell lines were infected with HIV and cultured in
the bottom chamber of a transwell culture device (Ref. 3427; Costar, Osi, Maurepas, France). CD8/ cells were added in the top chamber at different
ratios. The experiment was otherwise similar to those described for Fig. 2. RT activity is expressed as cpm/50 ml supernatants. Results from one
representative experiment are shown. Background RT activity in wells containing CD8/ or uninfected CD4/ alone was 1800 cpm. (A) Clone 141
and HIVLAI-infected autologous EM47 CD4/ T cell line were separated by a semipermeable membrane. (B) Clone 141 and HIVLAI-infected heterologous
S26 CD4/ T cell line were separated by a semipermeable membrane.
replication in heterologous CD4/ T cell line, whereas setting of coculture experiments and was found to remain
constant for several weeks. At the end of HIV-inhibitoryautologous HIV-infected CD4/ T cell line was suscepti-
ble to direct lysis by clone 141. assays, the CD8/ T cells present in the coculture had
high lytic activity against autologous targets coated withCytotoxic activity was measured 7 days after antigen-
specific stimulation and at various time points after the the cognate peptide (data not shown). Flow cytometry
analysis demonstrated that both CD4/ and CD8/ T cells
remained viable during the coculture, showing that inhibi-
tion of viral replication was not due to the suppression
of CD4/ T cell lines. When direct lysis of HIV-producing
cells was not allowed, i.e., against heterologous HIV-
producing cells, HIV inhibition ceased 2 or 3 weeks after
the beginning of the coculture (Fig. 2B), whereas HIV
inhibition against autologous CTL-sensitive CD4/ T cell
line was maintained until the end of the coculture experi-
ment (Fig. 2A). These results suggest that CTL-mediated
lysis may reduce viral replication, although direct demon-
stration would require an HIV-specific CTL clone that
does not produce a suppressive factor(s). The implication
of lysis of infected cells in the control of HIV replication
was refuted by HIV replication after removal of CD8/ T
cells from cocultures (11, 37). However, CTL lysis re-
quires synthesis of viral proteins in target cells, and fac-
tors secreted by CD8/ T cells inhibit viral transcription
(41–44). So, it is possible that in the presence of soluble
inhibitor(s), HIV-infected cells could not synthesize viral
antigens, and could not present them to CTL and thus
avoid a physical destruction by a cytolytic mechanism.
The ability of CD8/ T cells from HIV-infected individu-
als to suppress viral replication was first described by
FIG. 4. Lysis of CD4/ T cell lines by clone 141. CTL assays were
Walker et al. (11) and confirmed by several workers. Theconventional 4-hr chromium-51 release assays (40). For peptide
inhibition of HIV production is, at least in part, mediatedassays, target cells were labeled for 1 hr with 3.7 MBq of Na251CrO4
(1 1 106 cells) and washed, and synthetic peptides were added just by diffusible factor(s) (12, 13). However, these experi-
before mixing the target and effector cells. (A) Autologous (EM47) and ments were conducted with CD8/ polyclonal T cell lines
heterologous (S26) CD4/ T cells were incubated with medium or pep-
and an important question remains unanswered: does atide 25-17 (KTLRAEQASQEVKNWMTET, aa 302–320 from HIV p24gag)
monoclonal CD8/ T cell population possess both anti-at 1 mg/ml and used as target cells. (B) CD4/ T cells were infected
with HIVLAI for 13 days and used as target cells. gen-specific cytolytic activity and the ability to secrete
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